Aksamon solution and / v / m / n / a 15mg / ml 1ml amp 10 pcs

Description

Composition
Active substance:
1 ml contains: ipidacrine hydrochloride monohydrate (in terms of anhydrous) – 5 mg or 15 mg.
Excipients:
0.1 M solution of hydrochloric acid – to pH 3.00; Water for injection – up to 1 ml.
Description:
Transparent colorless liquid.
Product form:
A solution for intramuscular or subcutaneous administration of 5 mg / ml or 15 mg / ml. 1 ml of the drug in the ampule c point or ring fracture of a colorless glass. 5 vials are placed in blisters of PVC film. Two blisters are placed in a pile of cardboard. In each pack put the instructions for use.
Contraindications
Hypersensitivity to any component of the drug, epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, bradycardia, bronchial asthma, mechanical bowel obstruction or urinary tract, vestibular disorders, gastric ulcer or duodenal ulcer in the acute stage, children under 18 years of age (no systematized data on the use in children).
Be wary of: gastric ulcer and duodenal ulcer, thyrotoxicosis, diseases of the cardiovascular system, obstructive diseases of the respiratory system, or a history of acute respiratory diseases. If you have one of these diseases, before taking the drug should consult a doctor.
Indications
Disorders of the peripheral nervous system: mono- and polyneuropathy, poliradikulopatii, myasthenia gravis, myasthenic syndrome and various etiologies; CNS diseases: bulbar paralysis and paresis; recovery period of organic CNS lesions accompanied by motor disabilities; intestinal atony.
Interaction with other drugs
Aksamon® enhances sedation in combination with drugs that depress the central nervous system. Action and side effects are amplified when combined with other cholinesterase inhibitors, and m-nicotinic means. In patients with myasthenia increases the risk of a cholinergic crisis if Aksamon® applied simultaneously with other cholinergic agents. It increases the risk of bradycardia when to start treatment with Aksamon® used beta-blockers. Weakens the inhibitory effect on neuromuscular transmission and carrying excitation of peripheral nerves local anesthetics, aminoglycosides, potassium chloride. Aksamon® be used in combination with nootropics. Alcohol increases the side effects of the drug.
Overdose
Symptoms: decreased appetite, bronchospasm, lacrimation, sweating, pupillary constriction, nystagmus, increasing motility of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, blood pressure, anxiety, worry, agitation , anxiety, ataxia, seizures, coma, speech disorders, drowsiness and weakness.
Treatment: using m-cholinergic antagonists (atropine, Trihexyphenidyl, metacin et al.), Symptomatic therapy.
pharmachologic effect
Pharmacological group:
Cholinesterase inhibitor.
Pharmacodynamics:
Aksamon® – a reversible cholinesterase inhibitor, directly stimulates the holding pulse in the neuromuscular junction and in the central nervous system (CNS) due to blockade of potassium channels of the membrane. Enhances the effect on the smooth muscle is not only acetylcholine, but also adrenaline, serotonin, histamine and oxytocin. Aksamon® has the following pharmacological effects: – improves and stimulates the conduction of impulses in the nervous system and neuromuscular transmission; – improves conduction in peripheral nervous system disorders due to injury, inflammation, effects of local anesthetics, some antibiotics, potassium chloride, etc .; – increases the contractility of smooth muscle organs under the influence of acetylcholine agonists adrenaline, serotonin, histamine and oxytocin receptors, except for potassium chloride; – improves memory, slows down the development of dementia progradiently. It does not have a teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action. No effect on the endocrine system.
Pharmacokinetics:
In subcutaneous and intramuscular administration is rapidly absorbed. The maximum blood concentration is reached after 25-30 min after administration. Binding to plasma proteins – 40-50%. The drug rapidly enters the tissue. It is metabolized in the liver. Excretion via the renal drug (primarily by tubular secretion and only 1/3 by glomerular filtration) and extrarenal (through the gastrointestinal tract). The half-life of the drug when administered parenterally Aksamon® is 2-3 hours. After parenteral administration, 34.8% of the dose of the drug excreted in the urine in an unmodified form.
Pregnancy and breast-feeding
Use of the drug increases the tone of the uterus and can lead to premature delivery, so ipidacrine contraindicated during pregnancy. Data on the use of the drug during breast-feeding are not available.
Conditions of supply of pharmacies
Prescription.
side effects
The frequency of adverse reactions that can occur during application of the preparation, is shown in the following classification: very frequent (> 1/10 destinations), frequent (1 / 10-1 / 100 appointments), infrequent (1 / 100-1 / 1000 destinations), rare (1 / 1000-
4 1/10000 destinations), very rare (
Mental disorders: rare – drowsiness.
Disorders of the nervous system: rare – dizziness, headache, convulsions; unknown frequency – tremor.
Violations by the organ of vision: unknown frequency – cramps.
Violations of the heart: Often – palpitations, bradycardia; unknown frequency – chest pain.
Disorders of the respiratory system, chest and mediastinum: infrequent – increased allocation bronchial secretions.
Disorders of the gastrointestinal tract: often – excessive salivation, nausea; infrequent – vomiting; rare – diarrhea, epigastric pain.
Violations of the liver and biliary tract: unknown frequency – jaundice.
Violations of the skin and subcutaneous tissue disorders: infrequent – itching, rash.
General disorders and at the injection site: common – sweating; infrequent – general weakness; unknown frequency – hypothermia.
Salivation and bradycardia can be reduced m-holinoblokatorami (atropine, Trihexyphenidyl, metacin et al.).
In case of itching or rashes should stop taking the drug. In other cases, reduce the dose or short-term (1-2 days) interrupt taking the drug.
If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
During the treatment should refrain from driving, other vehicles and mechanisms, as well as from activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a place protected from light at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Subcutaneously or intramuscularly. Dose and duration of treatment is determined individually depending on the severity of the disease. Disorders of the peripheral nervous system: mono and polyneuropathies various genesis, poliradikulopatii: subcutaneously or intramuscularly 5-15 mg 1-2 times daily, a course of 10-15 days (in severe cases – up to 30 days); Further treatment is continued tablet form of the drug; myasthenia gravis and myasthenic syndrome: subcutaneous or intramuscular injection of 15-30 mg 1-3 times a day with a further transition to tablet form. The total course of treatment is 1-2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months. CNS diseases: bulbar paralysis and paresis: subcutaneous or intramuscular injection 5-15 mg 1-2 times a day, the course of 10-15 days; Further, switching to tablet form where possible; Organic recovery period CNS lesions accompanied by motor disturbances: intramuscular injection of 10-15 mg 1-2 times daily, a course of 15 days; Further, switching to tablet form, if possible. Treatment and prevention of intestinal atony: initial dose – 10-15 mg 1-2 times a day for 1-2 weeks.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist